Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - ENDO HEALTH SOLUTIONS INC. | d8k.htm |
 grow.
collaborate. innovate. thrive.
ENDO PHARMACEUTICALS
Citi Healthcare Conference
March 1, 2011
Exhibit 99.1 |
 grow.
collaborate. innovate. thrive. 2
FORWARD LOOKING STATEMENTS
This presentation contains forward-looking statements within the meaning of the Private
Securities Litigation
Reform
Act
of
1995.
Statements
including
words
such
as
“believes,”
“expects,”
“anticipates,”
“intends,”
“estimates,”
“plan,”
“will,”
“may,”
“look forward,”
“intend,”
“guidance,”
“future”
or similar
expressions are forward-looking statements. Because these statements reflect our
current views, expectations and beliefs concerning future events, these
forward-looking statements involve risks and uncertainties. Investors should note
that many factors, as more fully described under the caption “Risk
Factors”
in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange
Commission and as otherwise enumerated herein or therein, could affect our future
financial results and could cause our actual results to differ materially from those
expressed in forward-looking statements contained in our Annual Report on Form
10-K. The forward-looking statements in this presentation are qualified by
these risk factors. These are factors that, individually or in the aggregate, could cause our
actual results to differ materially from expected and historical results. We assume no
obligation to publicly update any forward-looking statements, whether as a result
of new information, future developments or otherwise. ©2011 Endo Pharmaceuticals
Inc. |
 STRONG
OPERATING PERFORMANCE 16% 3-YEAR CAGR FOR REVENUE*
* Revenue CAGR 2007-2010.
$mm
Sustaining our Growth
3
Revenue
Cash Flow from Operations
grow. collaborate. innovate. thrive.
©2011 Endo Pharmaceuticals Inc. |
 grow.
collaborate. innovate. thrive. ©2011 Endo Pharmaceuticals Inc.
NEW TESTOSTERONE REPLACEMENT THERAPY
14
million
men
suffer
with
hypogonadism
in
US
9% are treated
Market TRx Net Sales: >$1.2B
Growth Rate: approximately 20% CAGR last 5 years
Gels have the greatest utilization in the TRT market: ~72%
PCPs account for majority of TRT prescriptions:
More than 60% through Primary Care Physicians
Approximately 30% through specialty (Urologists/Endocrinologists)
Method of Payment for TRT class:
Approximately 80% Commercial
Approximately 12% Government
Remainder from Cash Payment
4
©2011 Endo Pharmaceuticals Inc. |
 grow.
collaborate. innovate. thrive. 5
DIVERSIFICATION OF BUSINESS
2008 ($1.26B)
2011E ($2.35B -
$2.45B)
Diversifying
our revenues through organic and strategic growth
©2011 Endo Pharmaceuticals Inc. |
 grow.
collaborate. innovate. thrive. 6
ENDO’S INTEGRATED BUSINESS MODEL
©2011 Endo Pharmaceuticals Inc. |
 grow.
collaborate. innovate. thrive. 7
2011 ENDO GUIDANCE
Guidance
Revenue range
$2.35BN -
$2.45BN
Adjusted diluted EPS range
$4.20 -
$4.30
Reported (GAAP) diluted EPS range
$2.43 -
$2.53
©2011 Endo Pharmaceuticals Inc. |
 grow.
collaborate. innovate. thrive.
ENDO PHARMACEUTICALS |
 grow.
collaborate. innovate. thrive. 9
9
RECONCILIATION OF NON-GAAP MEASURES
9
For an explanation of Endo’s reasons for using non-GAAP measures, see Endo’s
Current Report on Form 8-K filed today with the Securities and Exchange Commission
Reconciliation of Projected GAAP Diluted Earnings Per Share to Adjusted Diluted Earnings Per
Share Guidance for the Year Ending December 31, 2011 Lower End of Range
Upper End of Range
Projected GAAP diluted income per common share
$2.43
$2.53
Upfront and milestone-related payments to partners
$0.35
$0.35
Amortization of commercial intangible assets and inventory step-up
$1.33
$1.33
Acquisition and integration costs related to recent acquisitions.
$0.26
$0.26
Interest expense adjustment for ASC 470-20 and the amortization of
the premium on debt acquired from Indevus
$0.16
$0.16
Tax effect of pre-tax adjustments at the applicable tax rates and
certain other expected cash tax savings as a result of recent
acquisitions
($0.33)
($0.33)
Diluted adjusted income per common share guidance
$4.20
$4.30
The company's guidance is being issued based on certain assumptions including:
•Certain of the above amounts are based on estimates and there
can be no assurance that Endo will achieve these results
•Includes all completed business development transactions as of
February 28, 2011 ©2011 Endo
Pharmaceuticals Inc. |
 grow.
collaborate. innovate. thrive.
ENDO PHARMACEUTICALS
Citi Healthcare Conference
March 1, 2011 |